{"product_id":"azenta-five-forces-analysis","title":"Azenta Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAzenta faces moderate supplier power and high buyer scrutiny in a niche life-sciences tools market where specialization raises entry barriers but innovation and M\u0026amp;A keep competitive pressure intense; substitutes and regulatory shifts add episodic threats that shape pricing and R\u0026amp;D choices. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Azenta’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Component Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAzenta depends on niche suppliers for precision actuators and custom optics used in its automated storage and robotic arms, with fewer than five global vendors able to meet biotech tolerances; in 2024 supplier concentration contributed to a 6–9% input-cost sensitivity for instrument margins. Any single-vendor disruption or a 10–15% price rise can delay shipments by 6–12 weeks and cut gross margin by ~150–300 basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReagent and Chemical Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe genomic services division depends on high-purity reagents and chemical consumables supplied mainly by a few large life-science firms (Thermo Fisher, Merck, Agilent), giving suppliers strong bargaining power; these inputs represent roughly 12–18% of lab operating costs and are critical for sequencing accuracy, so Azenta has limited room to push prices down. The specialized chemistries create high switching costs—revalidation can take weeks and cost tens of thousands—locking Azenta into supplier relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Technical Labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe supply of specialized labor—robotics engineers and genomic scientists—is a critical input for Azenta’s service-led model, and as of 2025 demand outstrips supply: US biotech job openings grew 12% year-over-year in 2024 and median genomic scientist pay rose to about $120,000 in 2024, giving these workers strong bargaining power over compensation; Azenta must match or exceed market packages (total comp uplifts of 15–25% vs. 2022) to avoid talent loss to Big Pharma and tech firms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining biological sample integrity needs advanced cold-chain logistics and specialized transport; Azenta relies on external providers for ultra-low temperature shipping across borders, where losses can cost millions per batch. In 2024, certified biological shippers numbered only a few dozen globally, giving these firms moderate pricing leverage over Azenta’s sample-management margins, though long-term contracts and vertical investments limit rate volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew dozen certified shippers globally (2024)\u003c\/li\u003e\n\u003cli\u003eUltra-low temp transport critical—losses can cost millions\u003c\/li\u003e\n\u003cli\u003eSuppliers hold moderate pricing leverage\u003c\/li\u003e\n\u003cli\u003eAzenta offsets risk via long-term contracts and investments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Infrastructure and Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAzenta relies on third-party cloud and enterprise software to process \u0026gt;100PB of genomic and cold-storage data; AWS, Microsoft Azure, and Google Cloud account for ~60% of global cloud revenue in 2024, giving them leverage via multi-year contracts and complex migrations.\u003c\/p\u003e\n\u003cp\u003eThese suppliers can raise subscription fees or mandate security upgrades, squeezing Azenta’s margins—cloud costs for data-intensive biotech can reach 10–20% of OPEX; a single 10% fee hike would add millions annually.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eDependency: \u0026gt;100PB data, major cloud vendors dominant\u003c\/li\u003e\n\u003cli\u003eContract lock: multi-year, migration complexity\u003c\/li\u003e\n\u003cli\u003eCost risk: cloud ~10–20% OPEX; fee hikes multiply costs\u003c\/li\u003e\n\u003cli\u003eSecurity mandates: mandatory updates raise CAPEX\/OPEX\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power: hardware, reagents, talent \u0026amp; cloud drive 30–50% lab cost pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-strong power: \u003cbr\u003especialized hardware vendors (\u0026lt;5) drive 6–9% input-cost sensitivity; reagent suppliers (Thermo Fisher, Merck, Agilent) account for ~12–18% lab costs; talent pay rose ~12% in 2024 to $120k median; certified ultra-low shippers only few dozen (2024); cloud vendors (AWS\/Azure\/GCP) = ~60% market, cloud = 10–20% OPEX.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eMetric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHardware vendors\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5 vendors; 6–9% cost sensitivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003e12–18% lab costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalent\u003c\/td\u003e\n\u003ctd\u003eMedian $120k; +12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShippers\u003c\/td\u003e\n\u003ctd\u003eFew dozen certified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003e60% market; 10–20% OPEX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Azenta that uncovers competitive drivers, supplier and buyer power, threats from substitutes and new entrants, and identifies disruptive forces and strategic levers to protect market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear one-sheet Porter's Five Forces for Azenta—quickly assess supplier\/customer power, rivalry, entry threat, and substitutes to guide strategic moves and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Large Pharmaceutical Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA sizable share of Azenta’s revenue comes from a handful of pharma\/biotech giants—about 45% of 2024 revenue was concentrated in top 10 customers—giving these buyers strong bargaining power to demand volume discounts and bespoke SLAs. Those clients can push pricing down or require costly customizations; Azenta must therefore balance competitive contracts to retain anchor accounts while protecting margins (gross margin 2024: ~34%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Integrated Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOnce a lab integrates Azenta’s automated storage and inventory systems, switching costs—software retraining, hardware replacement, and workflow revalidation—can exceed $250k and 6–12 months, sharply lowering immediate customer bargaining power.\u003c\/p\u003e\n\u003cp\u003eProprietary firmware and LIMS (lab information management systems) integrations create technological lock-in, making customers dependent on Azenta for upgrades and support.\u003c\/p\u003e\n\u003cp\u003eStill, initial sales remain buyer-driven: procurement cycles average 9 months with \u0026gt;30% of contracts won through competitive RFPs and price concessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBudget Constraints in Academic Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic and government labs, which accounted for about 38% of life-science consumables spending in 2024, face fixed grant budgets and are highly price-sensitive, pushing Azenta to match lower-cost manual workflows or local providers to stretch funds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Comprehensive Data Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern customers demand integrated solutions pairing physical sample storage with digital genomic data and analytics, a trend led by genomics market growth to $34.8B in 2024 and 12.6% CAGR (2024–2030).\u003c\/p\u003e\n\u003cp\u003eThis gives buyers leverage to push Azenta to expand beyond storage into end-to-end services; losing that could drive customers to full-service CROs, which captured ~18% of life-science outsourcing spend in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCustomers force bundled offerings\u003c\/li\u003e\n\u003cli\u003eGenomics market $34.8B (2024)\u003c\/li\u003e\n\u003cli\u003eCROs ~18% outsourcing share (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers in genomics can choose among Illumina, Thermo Fisher, BGI and Novogene, raising price and turnaround pressure; sequencing revenue is highly commoditized with unit costs falling ~15–25% annually through 2024, so switching is low-friction.\u003c\/p\u003e\n\u003cp\u003eAzenta’s sample-management services are stickier but face churn risk: Azenta reported 2024 revenue $1.02bn, up 8%—forcing continual quality, SOP, and TAT (turnaround time) improvements to retain clients.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple top competitors: Illumina, Thermo Fisher, BGI, Novogene\u003c\/li\u003e\n\u003cli\u003eSequencing unit-cost decline ~15–25%\/yr to 2024\u003c\/li\u003e\n\u003cli\u003eAzenta 2024 revenue $1.02bn, +8% YoY\u003c\/li\u003e\n\u003cli\u003eSample management more specialized, lower switch rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTop‑10 buyers squeeze Azenta margins despite lock‑in; genomics market stays buyer‑driven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge pharma buyers (top 10 = ~45% of 2024 revenue) exert high bargaining power via volume discounts and bespoke SLAs, pressuring Azenta’s ~34% gross margin; switching costs (≥$250k, 6–12 months) and LIMS lock‑in lower short‑term leverage. Academic\/government price sensitivity and competing sequencers (Illumina, Thermo Fisher, BGI) plus CROs (18% outsourcing share, 2024) keep procurement buyer-driven.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑10 customer share\u003c\/td\u003e\n\u003ctd\u003e≈45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e≈34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost \/ time\u003c\/td\u003e\n\u003ctd\u003e≥$250k \/ 6–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAzenta revenue\u003c\/td\u003e\n\u003ctd\u003e$1.02bn (+8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics market\u003c\/td\u003e\n\u003ctd\u003e$34.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO share\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAzenta Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Azenta Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or samples—fully formatted, professionally written, and ready for download and use the moment you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747184488825,"sku":"azenta-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/azenta-five-forces-analysis.png?v=1772195739","url":"https:\/\/growthsharematrix.com\/products\/azenta-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}